New drug cocktail aims to beat Hard-to-Treat leukemia

NCT ID NCT04231851

Ongoing Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a combination of two drugs—CPX-351 (a chemotherapy) and glasdegib (a targeted pill)—in 30 people with acute myeloid leukemia (AML) that is either linked to a prior blood disorder or caused by previous cancer treatment. The main goal is to see how many patients are alive and cancer-free after 6 months. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (a chemotherapy drug combo) and glasdegib (a targeted therapy pill)
What this could lead to: If successful, this combination could offer a new treatment option for people with certain types of AML that are harder to treat.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drugs can cause serious side effects, and it's not yet known if the combination works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES

Contacts and locations

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine

Orange, California, 92868, United States
University of California, Davis

Sacramento, California, 95817, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.